The University of Texas MD Anderson Cancer Center, a substantial cancer establishment, demonstrated the tangible effects of substantial infection prevention and control (IPC) procedures during the COVID-19 pandemic.
A study featured in the American Journal of Infection Control depicted a noticeable reduction in healthcare-associated infections (HAIs). The investigators looked at the monthly incidence rate (IR) of HAIs from September 2016 to March 2022, a stretch spanning 42 months pre-pandemic and 25 months during the pandemic.
The hospital provided medical intervention to over 1,800 COVID-19 patients during that time. Beefed-up IPC measures during the pandemic constituted frequent use of personal protective equipment, elevated contact preventive measures, and a renewed focus on hand hygiene. Healthcare-associated infections scrutinized during the study included lab-determined Clostridioides difficile infection (Li-CDI), infections resulting from multidrug-resistant organisms (MDROs), hospital-indigenous respiratory viral infections (RVIs), and device-related infections. Overall, specific healthcare-associated infections such as Li-CDI, central line-associated bloodstream infections, and collective nosocomial RVIs experienced a marked reduction in their incidence rate during the pandemic.
The incidence rate of infections arising from individual viruses, like influenza and the respiratory syncytial virus, also saw a decrease. However, the incidence rates of catheter-associated urinary tract infections, ventilator-associated events, and MDROs remained comparatively stable between the two periods.
This reduction of HAIs at MD Anderson Cancer Center contradicts the usual trend seen in many U.S. healthcare settings, which anecdotally saw a surge in HAIs during the pandemic. The research says that the incidence rate of MDROs in COVID-19-specific wards was five times higher than other patient wards. This observation aligns with data from other hospitals globally that showed an uptick in MDRO HAIs during the pandemic, especially in COVID-19 patients. It remains uncertain, however, about the exact impact of particular IPC measures (like universal masking, use of face shields, and hand hygiene). The practicability of upholding these measures, such as continual masking in patient care, in the forthcoming respiratory viral seasons will be evaluated in subsequent studies. Coincidentally, a naturally occurring Yamagata lineage flu B virus has not been recorded since the initial COVID pandemic months in March 2020. The combined booster shots were universally advised for all Americans aged 12 and above as of September 2022.
Demographics data showed a lower percentage of Black and multiracial nursing home inhabitants in the South and Southeast regions were updated on their COVID vaccinations. Researchers found no positive results in bats, bat droppings, and village fruits from the first patient’s residential and forested area. Notably, median SARS-CoV-2 viral loads rose from symptom onset and reached a peak on the fourth or fifth day of symptoms. Wastewater tracking in the US also showed a downward trend, with a new global update showing a further increase in EG.5 proportion. Intriguingly, researchers found SARS-CoV-2 viral RNA in coronary atherosclerotic plaques in all patients—regardless of the extent of plaque buildup.
Authors of the study synthesized symptoms from patients post-confirmed COVID-19 infection, resulting in a list of 89 symptoms and the 30 most recurrent symptoms. There were no significant disparities in risk among COVID patients with chronic conditions and healthy immune systems, or older unvaccinated patients. In June, the CDC’s Advisory Committee on Immunization Practices recommended RSV vaccination for adults aged 60 years and older.
Source: https://www.cidrap.umn.edu/healthcare-associated-infections/enhanced-ipc-measures-cancer-center-linked-reduced-infections